Abstract. Human lymphocytes remain one of the most promising target cells for gene therapy. Gene modified lymphocytes have been successfully used to treat ADA-deficient patients and to control GvHD after allogeneic bone marrow transplantation. Since activation and proliferation of T cells is necessary for efficient retrovirus-mediated gene transfer and subsequent selection of transduced cells, mononuclear cells (MNC) from steadystate and G-CSF stimulated peripheral blood were activated by short exposure to the mitogen phytohemagglutinin (PHA) and/or the anti-CD3 antibody OKT3 in the presence of different concentrations of recombinant interleukin-2 (11-2). Using OKT3 (10 or 30 ng/ml) and 11-2 (100 U/ml), T cells expanded efficiently during a 14-day culture period. Cell expansion was similar under serum-free conditions. The immunophenotypic profile over time showed a marked increase in CD8+ cells leading to a reversed CD4/CD8 ratio of 1:2 and a slight increase in CD56+ cells. Supernatant-based centrifugational transduction of primary human T lymphocytes was compared with supernatant transduction on the extracellular matrix protein fibronectin. Transduction with cell-free retrovirus-containing supernatant in tissue culture flasks coated with human plasma fibronectin led to significantly higher transduction efficiencies (20.0±7.5%) than centrifugational transduction in uncoated culture flasks (13.6±5.1%)(p=0.041). To both rapidly characterize transduced cells and to isolate these from residual non transduced but biologically equivalent cells, an amphotropic Mo-MuLV based retroviral vector containing the intracytoplasmatically-truncated human lowaffinity nerve growth factor receptor (~LNGFR) eDNA as a marker gene was used. FACS sorting of T cells after transduction resulted in > 90 % LNGFR+ cells and was much faster than enrichment of transduced cells through growth in G418-selection medium. These results show that supernatantbased retroviral gene transfer into primary human T lymphocytes can be enhanced by extracellular matrix proteins such as fibronectin approaching levels of transduction that can otherwise only be achieved by cocultivation of virus-producing cells with target cells. Ectopic expression of a cell surface protein can be used to rapidly and conveniently quantitate transduction efficiency through FACS analysis and to efficiently enrich transduced cells through FACS sorting.
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Introduction
Retroviral vector mediated gene transfer is currently used in many gene marking and gene therapy protocols for advanced cancer, HIV infection [7] [8] [9] , and the treatment of inherited and acquired diseases [10] [11] [12] [13] .Genetically modified peripheral blood lymphocytes have been used to treat adenosine deaminase (ADA) deficient patients [14-21] and patients developing graft-versus-host disease (GvHD) after allogeneic bone marrow transplantation [3, 22] . Because efficient and stable gene delivery is central to all lymphocyte-based gene therapy, the primary limitation of using retroviral vectors for genetic modification of T lymphocytes has been the inefficiency of gene transfer by standard supernatant transduction ranging from 0.1-10 % [15, 17, 20, [23] [24] [25] . To overcome this problem, different improved supernatant-based transduction protocols have been proposed [26, 27] thus avoiding cocultivation of primary cells with the retrovirus packaging cell line [3, 17, 24] which for various safety reasons is not desirable for clinical use.
Recently, it has been shown that supernatant-based retroviral transduction of hematopoietic stem cells can be enhanced through colocalization of retrovirus particles and target cells on specific domains of fibronectin. Since activated T cells express very late antigen (VLA)-4 and VLA-5 [28-32], integrins known to interact with fibronectin [31,33],we examined whether fibronectin would also increase gene transfer into human T cells.
In this study, we have compared several methods for blood-derived MNC activation and subsequent proliferation of T cells. Furt-292 hermore, we demonstrate efficient transduction of primary human T cells with cell-free supernatant containing a retroviral vector on fibronectin-coated surfaces. Through ectopic expression of a cell surface protein (~LNGFR), transduced T cells cells could be rapidly and accurately identified through FACS analysis and were efficiently enriched through FACS sorting.
Materials and Methods

Primary cells and cell lines
After informed consent, mononuclear cells (MNC) were isolated from peripheral blood, bone marrow, or (rhGCSF-mobilized) leukaph eresis products by centrifugation on a Ficoll-gradient (density 1077g/I, Pharmacia, Freiburg, Germany) for 20 min at 20°C and washed twice with phophate-buffered saline (PBS, Gibco, Eggenstein, Germany) prior to use. For the cell expansion studies, MNC (1 x 10 6 cells/ml) were activated with soluble CD3-Mab (OKT-3: 10, 30, and 100 ng/ml; Cilag, Neuss, Germany), and/or phytohemagglutinin (PHA: 10 and 50 ug/rnl: Sigma, Deisenhofen, Germany) and recombinant human interleukin-2 (11-2; 25, 100, and 1000 D/ml; Proleukin, Chiron, Ratingen , Germany) and incubated in RPMI 1640 (Seromed, Biochrom, Berlin, Germany) supplemented with 10 % [vol/vol] heat-inactivated fetal calf serum (Hyclone Europe, Erembodegem, Belgium), 50 flM 2-mercaptoethanol, 2 mM glutamine, 1 mM sodium pyruvate, and 1 % penicillinstreptomycin (Gibco). Cells were cultured in 12-well plates (flat bottom multiwell tissue culture plate; Falcon 3043; 2 x 10 6 cells/well) and fed 4, 7, and 10 days after culture initiation. For retroviral transduction, MNC (2 x 10 6 cells/ml) were activated three to four days in tissue culture flasks (Falcon, Becton Dickinson, Heidelberg, Germany) with OKT-3 (10-30 ng/ml) and 11-2 (100 D/ml). Long-term cultures were set up in T-75 flasks (Falcon, Becton Dickinson, Heidelberg, Germany) at 2 x 10 6 cells/ml. Expanding cells were split every two to three days with 50% of the medium being replaced with fresh medium supplemented with 100 U of rh 11-2/ml. For expansion in serum-free media, cells were
